Tagged with B

China The latest news from Chinese pharma, including the latest on Sinopharm’s COVID-19 vaccine, how geopolitical tensions are affecting trade between China and India, and the country’s latest pharma billionaire.   China’s Sinopharm touts 100 percent antibody response for COVID-19 vaccine it’s already giving to workers https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving Tuesday, China’s state-run Sinopharm said (Chinese)…

Belgium Veronique Walsh, General Manager of Bristol Myers Squibb (BMS) – Benelux, explains her ambition to build a new company culture following the acquisition of Celgene. Walsh also lays bare the prospects for bringing innovation to Belgian patients and explains how BMS continues to deliver on its promise of transforming lives…

China I recently had the pleasure to moderate an event on the COVID-19 impact on the relationship between Doctor and Patient, attended by 50 executives of the French Healthcare community in China (Club Santé Chine). I would like to share here some learnings and personal thoughts.   One of the consequences…

China Chinese biotech CanSinoBIO is racing against the clock to have a COVID-19 vaccine ready to begin production in early 2021. The firm’s senior VP of International Business Pierre Morgon reflects on CanSinoBIO’s progress thus far and a timeline of what we can realistically expect if and when Chinese authorities give…

Korea Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to shed light on the company’s origins, its collaboration with Big Pharma, and the ease of gaining capital investment for a…

USA In a recent virtual town hall meeting hosted by BIO, two key leaders from the US FDA laid out how their organisation has adjusted in the wake of the COVID-19 crisis, at what stage of development diagnostics and therapeutics for the virus are, and the pandemic’s long-term effects – both…

Korea After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND) approval from the FDA.   Dr Kyung Suk Kim, Corestem’s CEO, recently spoke to PharmaBoardroom to give an update on…

China Founded by a veteran industry team, Arctic Vision recently celebrated its first anniversary and touts itself as the first innovative ophthalmology-focused biotech in China, with the mission of bringing innovative therapies from abroad to patients in China.   According to CEO and cofounder Dr Eddy WU, a company like Arctic…

Coronavirus The BIO International Convention was held digitally in June 2020, bringing together over 7,000 participants from around the world. In an R&D-focused session titled “Whiplash! How Covid-19 Will Radically Change Biomedical R&D Across the Globe,” moderator Andy Marshall of Nature Biotechnology brought together experts in biotech, pharma innovation and research.…

China Dr Eddy Wu, founder and CEO of new Chinese ophthalmology biotech Arctic Vision outlines the specific unmet ophthalmology needs in the Chinese market, the company’s burgeoning international partnerships, exciting portfolio, and Dr Wu’s own personal leadership journey.   From an R&D perspective … what is critical in ophthalmology is the…

China Yan Tan, CEO of Xbiome, the first AI-based microbiome drug development company in China, outlines the rationale behind the firm’s founding, what makes its technology platform unique, and the challenges of attaining funding for cutting-edge innovation.   Despite being a relatively new company, in 2019, we raised the most money…

China 2020 will certainly go down in history as a watershed year for the global community, as a new strain of coronavirus – later named SARS-CoV-19 – originating from the city of Wuhan in China circulated around the world in just months, wreaking havoc on economies and disrupting the lives of…